Health coaching
Our research shows that you can lose more weight when combining health coaching than using medication alone.
What is Wegovy?
Wegovy is a prescription weight loss treatment that contains the active ingredient semaglutide, belonging to a group of medications called GLP-1 receptor agonists.¹
It works by mimicking a naturally occurring hormone in the body called GLP-1, stimulating nerve receptors in the brain that control appetite, so you feel less hungry and have fewer cravings.2
Additionally, it stimulates the release of insulin from pancreatic beta cells, as GLP-1 is present in both the pancreas and the brain.2 Implementing behavioural change strategies alongside the treatment is known to be an effective method for weight loss.3
How effective is Wegovy?
Wegovy is proven to be an effective weight loss medication. Two large clinical trials have looked at how different doses of semaglutide affect weight loss. The findings were as follows:1,4
People taking the previous full therapeutic dose (2.4 mg weekly) lost an average of 15% of their body weight over 68 weeks.
Those taking the recently approved therapeutic dose (7.2mg weekly) lost up to 21.7% of their body weight over 72 weeks.
Those on a placebo lost 2.4% and 3.9% in the respective timeframes.
This shows that Wegovy can lead to significantly more weight loss than diet and exercise alone.
OTHER SOLUTIONS
Effective treatments for weight loss
Proven solutions to change your weight, mindset, and behaviours.
How does Wegovy work?
Wegovy contains the active ingredient semaglutide, which mimics a natural hormone that suppresses your appetite and reduces food cravings.2
Wegovy works by enhancing the effects of a natural gut hormone called GLP-1. Here’s what that means for you:1-3
Reduces appetite: Wegovy acts on areas of the brain that regulate hunger, helping you feel fuller sooner and reducing the urge to overeat.
Curbs cravings: By mimicking GLP-1, it lowers food cravings and makes it easier to make healthier choices.
Supports blood sugar control: It slows down how quickly food leaves your stomach and improves how your body uses insulin, helping to keep blood sugar levels steady.
Protects the heart: Clinical studies show semaglutide can lower the risk of cardiovascular events, such as heart attack and stroke, in people living with obesity and established cardiovascular disease.
Proven results: In large clinical trials, people taking Wegovy lost up to 20.7% of their body weight over 72 weeks, far more than lifestyle changes alone.
Why choose Numan for Wegovy?
Numan isn't just an online pharmacy. We’re a holistic health provider offering complete care to help you get the most from your treatment. When you choose Wegovy with Numan, you’ll also get access to:
Wegovy treatments
Wegovy is gradually introduced to your body through a process called dose titration. This means that your dose is increased step by step over several months to allow your body to adjust to the medication and to help minimise side effects.
It's important to note that not everyone will need the highest dose to maintain, and that your maintenance dose will depend on how you respond to treatment.
Wegovy treatment doses are as follows:5
| Dose | Use | Price |
|---|---|---|
| 0.25mg | Injected into the upper (subcutaneous) layer of the skin once a week. Dose is then titrated based on individual response. | £179 |
| 0.5mg | Injected into the upper (subcutaneous) layer of the skin once a week. Dose is then titrated based on individual response. | £209 |
| 1mg | Injected into the upper (subcutaneous) layer of the skin once a week. Dose is then titrated based on individual response. | £209 |
| 1.7mg | Injected into the upper (subcutaneous) layer of the skin once a week. Dose is then titrated based on individual response. | £249 |
| 2.4mg | Injected into the upper (subcutaneous) layer of the skin once a week. Dose is then titrated based on individual response. | £299 |
| 7.2mg | Injected into the upper (subcutaneous) layer of the skin weekly as three 2.4mg doses given together. The dose is then titrated based on individual response. | £359 |
Wegovy doses
0.25mg
Starting dose
0.5mg
Second dose, often prescribed after 4-6 weeks
1 - 7.2mg
Possible maintenance doses
Who is eligible for Wegovy?
Wegovy is designed for people who need extra support with weight management and meet certain medical criteria. It isn’t for everyone, but if you’ve struggled with weight loss in the past, it may be an option worth exploring.
Here’s what’s involved:6
Eligibility: You’ll usually need a BMI of 30 or more, or a BMI over 27 if you also live with a weight-related condition such as high blood pressure, cardiovascular disease, or type 2 diabetes.
Lifestyle support: Wegovy should only be used alongside healthy lifestyle and dietary changes.
When it’s considered: It’s aimed at people who have already tried more traditional weight loss methods without lasting success.
Assessment process: To be considered, you’ll first complete an online questionnaire about your health and weight history.
Clinical review: A Numan clinician will then carefully review your answers, your medical history, and your goals to decide if Wegovy is the right option for you.
Who should not take Wegovy?
Wegovy isn’t suitable for everyone. It should not be used if you:
Are pregnant, breastfeeding, or planning a pregnancy.
Have ever had an allergic reaction to semaglutide or any of its ingredients.
Have a personal or family history of medullary thyroid carcinoma (a rare type of thyroid cancer) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Have certain serious health conditions such as severe gastrointestinal disease or a history of pancreatitis.
How to take Wegovy
Taking Wegovy is straightforward with the right guidance. It comes as a pre-filled injection pen that you use once a week.
To take Wegovy, you first prepare (prime) the pen, choose an injection site - like your stomach or thigh - and inject the dose following the instructions. Dispose of the needle safely in the yellow sharps bin, and store your pen with the cap on until the next use.
Things you should know about Wegovy
The difference between Mounjaro and Wegovy
It can be difficult to choose the right weight loss medication. However, a consultation with a Numan clinician can help you make a more informed decision. Below is a short summary of what the main differences are between Mounjaro and Wegovy.1,7
| Mounjaro | Wegovy | |
|---|---|---|
| Achievable weight loss, according to research | Up to 22.5% | Up to 20.7% |
| Protects against heart disease | No | Yes |
| Dosage | One weekly injection | Weekly injections |
UK DOCTORS AND CLINICIANS
Your expert team
Specialists in medicine, nutrition, performance, and diagnostics.
Danielle Brightman
Clinical Director
MPharm PgDip PCert
Dr Grace Hatton
Women's Health Medical Lead
MBChB MPharm DTM&H MBA
Zoe Griffiths
VP of Behavioural Medicine
BSc (Hons) RD SCOPE
Shivani Sharma-Savani
Obesity Clinical Lead
MPharm PGCert PCert IP
Dr Aisha Jinnah
Numan Doctor
BSc MBBS MRCGP
Dr Alexandra Davidson
Numan Doctor
BSc (Hons) MBBS MRCGP AFHEA MA (Hons) AFMCP
Abby Watts
Senior Nurse Prescriber
BSc Adult Nursing, IP
Victoria Rogers
Head of AI Coaching and Behavioural Science
MSc BSc
Jess Uffindell
Registered Nutritionist
BANT CNHC BSc (Hons)
Faye Townsend
Coaching Operational Lead
AfN BSc BDA SENr (Registered Nutritionist)
Personalised health coaching
Health coaching is at the heart of our programme, designed to create lasting lifestyle changes. Paired with Wegovy’s appetite-regulating effects, our coaches provide guidance on building practical, sustainable habits in nutrition, exercise, sleep, and mindset.
Wegovy helps manage cravings, while our coaches enhance these benefits, offering advice on balanced meals, enjoyable movement, and effective routines for better health. Together, they give you the support needed to make meaningful progress and maximise your results.
/ "wl-app-")
Obesity: fighting the disease with effective treatment
Numan’s Weight Loss Programme tackles obesity with a fresh perspective, understanding it as a medical condition shaped by external factors.8 Our approach goes beyond conventional advice, incorporating treatments to provide a solid foundation for lasting lifestyle adjustments.
With obesity impacting a significant portion of the UK population, we offer a comprehensive solution that combines medical support with tailored guidance. By addressing the core drivers of weight gain, our programme empowers you to achieve and sustain a healthier weight with expert-led, compassionate care.
I feel I can live a longer, happier life with less risk of cardiovascular issues. I've struggled with being overweight for many years, so the impact has been life-changing.
I discovered an old bag of clothes and couldn’t believe how many of them fit me where I would have had no chance before. I feel amazing. I think I look much better than I ever did.
I want to be in good shape to enjoy life. But be happy as I’m doing it, rather than miserable. And I think I’ve managed that with the programme.
FAQS
Your questions answered
Medically reviewed by Hassan Thwaini
Clinical Pharmacist and Copywriter, Master of Pharmacy (MPharm)
KNOWLEDGE
Weight loss: what you need to know
References
1 Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949–63.
2 Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159–66.
3 Chu J, Zhang H, Wu Y, Huang Y, Zhu T, Zhou Z, et al. Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine. 2025;88(103464):103464.
4 McGowan BM, Bruun JM, Capehorn M, Pedersen SD, Pietiläinen KH, Muniraju HAK, et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12(9):631–42.
5 Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen. Org.uk. https://www.medicines.org.uk/emc/product/13799/smpc [Accessed 12th May 2025].
6 Overview | Semaglutide for managing overweight and obesity | Guidance | NICE. https://www.nice.org.uk/guidance/ta875
7 Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. The New England journal of medicine. 2022;387(3): 205–216.
8 Lee A, Cardel M, Donahoo WT. Social and Environmental Factors Influencing Obesity. [Updated 2019 Oct 12]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000-.
Start your treatment journey
Answer a few simple questions to get the treatment you need.